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Most solid tumors are comprised of cells with abnormal numbers of chromosomes, which 
result from chromosomal missegregation during mitosis. The increased rate of 
chromosome gains or losses is known as chromosomal instability (CIN) and may be 
implicated in early tumor development processes. Consequently, there has been significant 
interest in targeting CIN as a novel therapeutic intervention, especially since increased 
missegregation may impart drug sensitivity in cancer cells. To discover novel chemical 
modulators of faithful chromosome segregation, we employed a quantitative chromosome 
transmission fidelity (qCTF) assay previously used in a genetic screen for CIN phenotypes 
in Saccharomyces cerevisiae and adapted it for a high throughput screen of 418 
commercially-available kinase inhibitors. We generated a qCTF strain with increased drug 
sensitivity and weakened mitotic checkpoint in order to achieve sensitive and cost-effective 
detection of increases in CIN at minimal inhibitor concentrations. Using the adapted qCTF 
assay, we developed a pipeline for hit identification, false positive exclusion through 
additional phenotypic validation assays, and hit verification by colony sectoring assay. 4 
of the 418 kinase inhibitors were identified as compounds that significantly increased CIN 
and target the MAPK pathway, cell cycle regulation, and glycolysis in mammalian cells. 
Interestingly, our screen identified dabrafenib, an FDA-approved compound used to treat 
metastatic melanoma, as a potential aneugen. Yeast homologs of the mammalian targets 
were determined and deleted to identify possible drug targets in yeast. We proposed that 
HOG1, a key regulator of the hyperosmotic stress response, and BMH1, an isoform of the 
14-3-3 family of proteins, may play roles in maintaining chromosome transmission fidelity. 
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Altogether, this study establishes a high throughput pipeline that can be extended to larger 
compound libraries to identify drugs that elevate chromosome missegregation and cause 
lethal aneuploidy.  
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Chapter 1: Introduction 
Normal cellular function is dependent on the equal division of genetic material between 
two daughter cells. Failure to do so can have detrimental consequences, often resulting in 
diseases such as Down’s syndrome and cancer. This chapter reviews how chromosomal 
instability is implicated in cancer, the mechanisms by which errors in chromosome 
partitioning arise, a robust surveillance mechanism that detects and guards against 
chromosome missegregation, assays used to measure chromosomal instability, and yeast 
as a model organism for the high throughput study of modulators of chromosomal 
segregation.  
 
Chromosomal instability in cancer 
70-90% of human tumors are comprised of cells with abnormal numbers of chromosomes, 
which results from chromosomal missegregation during mitosis (Weaver & Cleveland, 
2006; Kops, Weaver, & Cleveland, 2005). This loss or gain of whole chromosomes at 
increased rates is  known as chromosomal instability (CIN) and has been implicated in 
early tumor development processes (Bakhoum & Compton, Chromosomal instability and 
cancer: a complex relationship with therapeutic potential, 2012). As a result, there has been 
significant interest in targeting CIN for novel therapeutic interventions, especially since 
increased missegregation rates have been shown to impart drug sensitivity in tumor cells 
and may even suppress tumor formation above some threshold CIN level (Janssen, Kops, 
& Medema, 2009). Moreover, whole chromosome missegregation can generate a diverse 
cell population, which contributes to the adaptability and evolvability of cancer cells 
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especially under selection pressures (Cahill, Kinzler, Vogelstein, & Lengauer, 199). The 
intratumor heterogeneity that results from CIN produces cells with a diverse set of 
genotypes, some of which may confer a selective advantage. These advantageous 
mutations allow a small population of cells to overcome selection pressures and ultimately 
result in the propagation of a clonal population that can proliferate even in the presence of 
the selection. However, too much chromosomal instability results in the massive loss of 
essential genes required for cell survival, and consequently, cells that demonstrate 
excessive CIN produce progeny that are highly aneugenic and often inviable. Recently, 
there has been increasing interest in exploiting CIN as a potential cancer therapeutic. 
Current developing therapeutics attempt to target specific mediators of chromosome 
segregation that are speculated to elicit a more pronounced effect in cancer cells, including 
Aurora B, which destabilizes MT-KT attachments, HSET, which maintains proper spindle 
polarity, and components in the autophagy pathway (Tanaka & Hirota, 2016). These 
therapeutics take advantage of the already defective chromosome segregation mechanisms 
present in cancer cells and further aggravate them in order to arrest the cell and induce 
apoptosis. 
 
Mechanisms of chromosomal missegregation 
There are four primary routes of chromosomal missegregation that occur during mitosis – 
defects in mitotic checkpoint, sister chromatid cohesion, microtubule-kinetochore 
attachments, and centrosome amplification. After cells have duplicated their genetic 
content, their chromosomes condense and line up in a single plane during metaphase. 
Spindle microtubules emanating from opposite poles then form the proper attachments to 
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kinetochores of both sister chromatids, and pull the chromatids apart. The cell undergoes 
cytokinesis, generating two daughter cells with equal partitioning of genetic material. 
Defects in several steps during mitosis can interfere with the faithful division of 
chromosomes.  
The mitotic checkpoint, also known as the spindle assembly checkpoint (SAC), 
senses the presence of unattached kinetochores and responds by delaying anaphase 
(Holland & Cleveland, 2009). More specifically, the SAC halts mitotic progression by 
sequestering the E3 ubiquitin ligase, anaphase promoting complex/cyclosome (APC/C), 
and prevents it from interacting with downstream mitotic substrates such as cell cycle 
regulators and securin (Kops, Weaver, & Cleveland, 2005). A compromised mitotic 
checkpoint results in premature entry into anaphase in spite of improper microtubule-
kinetochore attachments or chromosomal misalignments. As a result, sister chromatids 
may fail to separate and be inherited together, generating a daughter cell that is aneuploid 
(Figure 1.1).  
Defects in sister chromatid cohesion is an additional contributor to chromosomal 
missegregation. Cohesin is a protein that holds sister chromatids together until they are 
pulled towards the spindle poles during anaphase (Kops, Weaver, & Cleveland, 2005). 
During anaphase, cohesin is cleaved by separase, which is inhibited and sequestered by 
securin in metaphase (Kops, Weaver, & Cleveland, 2005). Abnormalities in cohesin 
degradation can cause sister chromatids to fail to separate during anaphase, resulting in 
aneuploid daughters. Similarly, chromosomal missegregation may also result from 
premature sister chromatid separation (Figure 1.1). Sister chromatid cohesion defects have 
been implicated in various cancers exhibiting chromosomal instability, including 
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Hodgkin’s lymphoma and human colorectal cancers (Sajesh, 2013; Barber, 2008). 
Furthermore, a study that sequenced 102 human genes related to yeast CIN genes identified 
11 somatic mutations in colorectal cancer, 10 of which play direct roles in sister chromatid 
cohesion (Barber, 2008). 
Another mechanism that affects the faithful partitioning of chromosomes is the 
establishment of faulty attachments of kinetochores to spindle microtubules. More 
specifically, merotelically attached kinetochores – single kinetochores that are attached to 
spindles from both poles – are undetected by the SAC because sufficient tension is 
generated by the microtubule-kinetochore attachments (Kops, Weaver, & Cleveland, 2005). 
Since MT-KT attachments are dynamic and constantly undergo disassociation and 
reassociation, errors in MT-KT attachment are often resolved (Thompson, Bakhoum, & 
Compton, 2010). However, failure to correct merotelic attachments results in lagging 
chromosomes, which may be inherited by a single daughter cell or become lost from both 
daughter nuclei and form individual micronuclei (Figure 1.1) (Kops, Weaver, & Cleveland, 
2005). Interestingly, in colorectal cancer cell lines, lagging chromatids were observed in 
the majority of cells exhibiting mitotic defects and high percentages of lagging chromatids 
have been found in breast, colon, and lung tumors (Thompson S. L., 2008). Regulation of 
KT-MT dynamics may present a therapeutic opportunity as exemplified by one study, 
which reported that overexpression of kinesins that promote MT-KT destabilization rescue 
chromosome missegregation phenotypes in tumor cell lines exhibiting increased CIN 
(Bakhoum, Thompson, Manning, & Compton, 2009). 
The final pathway to chromosome missegregation discussed in this chapter is 




Figure 1.1: Mechanisms of chromosomal missegregation (taken from Holland & Cleveland, 2009).  
 
two centrosomes migrating to opposite poles during mitosis. Additional centrosomes may 
be introduced through defects in centrosome duplication and result in the generation of 
multiple poles during cell division (Thompson, Bakhoum, & Compton, 2010). However, 
aneuploids generated from multipolar divisions are often inviable (Figure 1.1). More 
commonly, multiple centrosomes will cluster together to form two poles, creating an 
imbalance in the distribution of spindle microtubules and increasing the frequency 
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chromosome missegregation caused by merotely (Figure 1.1) (Holland & Cleveland, 
2009). Furthermore, aberrations in centrosome number has been found in various human 
tumors, including malignant breast, prostate, lung, and colon, and have been associated 
with chromosomal missegregation and resulting aneuploidy (Pihan, 1998). 
 
The Spindle Assembly Checkpoint (SAC) ensures faithful chromosome segregation 
Yeast have a robust surveillance mechanism called the spindle assembly checkpoint (SAC) 
that ensures the equal division of genetic material during mitosis. As described earlier, the 
main role of the SAC is to halt progression through mitosis by inhibiting the activity of the 
anaphase promoting complex/cyclosome (APC/C), which binds to and targets downstream 
cell cycle regulators for degradation by the proteasome (Lara-Gonzalez, 2012). The SAC 
is activated through its sensing of improper kinetochore-microtubule attachments that 
generate insufficient tension (Figure 1.2A). The primary components of the SAC – MPS1, 
Mad1, Mad2, Bub1, Bub3, BubR1 (Mad3 in yeast) – and their interactions are reviewed 
here. 
Assembly of the SAC is initiated by the phosphorylation activity of MPS1, which 
recruits the BUB1-BUB3 and MAD1-C-MAD2 complex to unattached kinetochores 
during prophase (Faesen, et al., 2017; Lara-Gonzalez, 2012). The MAD1-C-MAD2 core 
complex is formed during early mitosis when MAD2 binds MAD1 and transitions from an 
open (O-MAD2) to a closed conformation (C-MAD2). This complex is then recruited to 
unattached kinetochores, binds the BUB1-BUB3 complex, and can further recruit cytosolic 
O-MAD2. The bound O-MAD2 can then bind CDC20, an activator of APC/C, forming the 





Figure 1.2: The spindle assembly checkpoint. A) The SAC detects unattached kinetochores and delays 
anaphase by assembling the mitotic checkpoint complex. B) Formation of the mitotic checkpoint complex 
(taken from Faeson, et al., 2017). 
 
(MCC). The MCC is then fully assembled upon the binding of MAD2-CDC20 and 
BUBR1(or MAD3)/BUB3, and is the main inhibitor of APC/C (Figure 1.2B). The 
sequestration of APC/C then halts the cell in metaphase until the proper MT-KT 
attachments and chromosomal alignments are made. Afterwards, MCC disassembly allows 
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APC/C to bind to its activator, CDC20, ubiquitinate its downstream targets, and promote 
mitotic exit (Lara-Gonzalez, 2012).  
 
Measuring chromosomal instability in yeast 
Various assays have been developed to measure rates of chromosomal missegregation in 
yeast. One method that relies on the production of a red pigment was developed several 
decades ago in Saccharomyces cerevisiae and has been used in a genetic screen for mutants 
with abnormalities in chromosome segregation (Stirling, et al., 2012; Spencer, Gerring, 
Connelly, & Hieter, 1990). The classical chromosome transmission fidelity (CTF) assay, 
also known as the colony sectoring assay, makes use of a deficiency in purine biosynthesis 
caused by a ade2-101 mutation (Figure 1.3). Incomplete translation of the ade2 enzyme 
renders the cells unable to complete the synthesis of adenine and, consequently, cells with 
the ade2-101 mutation accumulate a visible red pigment. This mutation can be rescued by 
the presence of a chromosome fragment (CF) containing SUP11 which encodes a tRNA 
ochre suppressor. Thus, cells that contain the CF are unpigmented whereas cells that lose 
the chromosome fragment appear red. The loss of the CF can be observed after the fact by 
visual inspection of individual colonies, and the timing of the loss event can be determined 
by examining the area of the red sector. For instance, colonies that are half red and half 
white indicate CF loss during the first cell division after plating, and colonies with one 
quarter red sectors are indicative of CF loss during the second cell division. While this 
assay allows for the visual detection of CF loss and calculation of chromosome 
missegregation rates, tens of thousands of colonies are required in order to obtain an 






Figure 1.3: The classical chromosome transmission fidelity assay allows for the measurement of 
chromosome missegregation rates (taken from Stirling, et al., 2012).  
 
once in every 10,000 divisions in this strain (Spencer, Gerring, Connelly, & Hieter, 1990). 
Recently, a new method was developed for measuring CIN and similarly utilizes a 
chromosome fragment, termed “minichromosome” (MC). The quantitative chromosome 
transmission fidelity (qCTF) assay relies on a reporter/repressor system in which GFP 
expression is used to detect chromosome loss (Figure 1.4). A reporter consisting of three 
GFP repeats (3xGFP) is placed adjacent to a mating specific gene, MFA-1, on 
Chromosome IV. The MC, which is derived form a truncation in the native chromosome 
III, encodes a strong  repressor that binds to MFA-1 and inhibits the transcription of 
3xGFP. Thus, MC loss is indicated by GFP expression and the assay can be used to measure 
the rate of chromosomal missegregation. By observing the changes in GFP-positive 
frequency and accounting for the number of doublings, the MC loss rate can be determined. 
Moreover, flow cytometry can be used to easily detect and distinguish between populations 




Figure 1.4: The qCTF assay detects minichromosome loss. A) The qCTF assay uses a repressor/reporter 
module that results in GFP expression when the minichromosome (MC) is lost. B) MC+ and MC- 
populations are distinguishable through flow cytometry. (Figures are taken from Zhu et al., 2015) 
 
Using a mathematical model, we can quantify the rate of MC loss using only two 
parameters – the number doublings and the change in GFP-positive frequency. Assuming 
that events occur on a discrete time scale and equal doubling rates between cells that have 
the MC and cells that have lost it, the MC loss rate ( ) is a function of the initial GFP-

















* denote the initial and final  number  of cels containing the 
minichromosome, respectively. (Refer to the Extended Materials and Methods in Zhu, et 
al., 2015 for ful derivation of the equation). 
The  qCTF assay  has several advantages  over the classical  CTF for a  number  of 
reasons. The classical CTF is low throughput and requires the plating of at least 10,000 
colonies in  order to  observe  one  CF loss event in the  wildtype  CTF strain.  Accurate 
measurements of CF loss would then require the plating of even more colonies. In contrast, 
because the qCTF assay uses fluorescence as an indicator of chromosome missegregation, 
MC loss events can be detected by flow cytometry which can measure the fluorescence of 
several thousand cels  per second.  As a result, accurate  measurements  of chromosomal 
missegregation can be obtained with significantly reduced labor costs and more samples 
can  be tested simultaneously.  Thus, the  qCTF assay naturaly lends itself for  high 
throughput  biology, and is a suitable assay for large  genetic  or compound screens. 
Moreover, the qCTF is more sensitive than the classical CTF and is able to detect 2-3 fold 
changes in chromosome missegregation as demonstrated by a previous study that tested 
cellular response to treatment  with cancer and antifungal drugs (Figure  1.5).  The same 
study found that the qCTF assay is also able to detect approximately 100-fold increases in 
CIN. As a result, this thesis reports the use of the the qCTF assay for a chemical screen, 
taking advantage  of its  high throughput capacity,  high sensitivity in  detection  of smal 





Figure 1.5: The qCTF assay demonstrates sensitive detection of changes in CIN and a large dynamic 
range (taken from Zhu et al., 2015). 
 
Yeast as a model organism  
Saccharomyces cerevisiae is a great model organism for high throughput screens and the 
study of chromosome segregation for several reasons. Budding yeast have a fast replication 
time of approximately 100 minutes, can be easily manipulated genetically, and is 
inexpensive to grow and maintain. The entire genome has been completely sequenced with 
extensive annotations and can be accessed electronically (Botstein 1999). Moreover, this 
simple organism is a good model to study chromosome partitioning because several 
mechanisms and genes involved in chromosome segregation are conserved between 
between yeast and higher eukaryotes. Additionally, budding yeast can tolerate aneuploidy 
without severe consequences on cell viability and various established assays exist for 
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studying chromosome instability in yeast, including a colony sectoring assay, a-like faker 
assay, and the quantitative chromosome transmission fidelity assay detailed earlier.  
 
Motivation and summary 
Provided that there are several routes through which the faithful transmission of 
chromosomes can be compromised, one can appreciate that chromosome segregation is an 
intricate and carefully choreographed process. To further elucidate pathways that 
contribute to chromosome missegregation, the qCTF assay was previously used in a genetic 
screen to identify mutants with increased or decreased CIN phenotypes. This work extends 
the study of CIN beyond that of genetic perturbations and investigates the use of the qCTF 
assay to identify chemical modulators of CIN. We report modifications to the qCTF assay 
for high throughput compound screens. Moreover, we establish a pipeline that includes 
false positive exclusion and hit verification procedures, and demonstrate that this optimized 
qCTF assay can accurately identify potential aneugens in yeast. From our identified hits, 
we attempt to identify the drug targets of our compound hits in yeast to discover unknown 





Chapter 2: Materials & Methods 
Chemical transformations in yeast 
Yeast transformations were performed as instructed by the micro-scale protocol provided 
by the Frozen-EZ Yeast Transformation II kit (Zymo Research). An overnight culture 
grown in SD media was back-diluted to an OD600 of 0.2. The refreshed culture was grown 
to log phase (OD600 of 0.6) and cells were pelleted in a microcentrifuge at 11000 rpm for 
4 minutes. The pellet was then washed with a proportional amount of EZ1 solution and 
resuspended in EZ2 solution. 5 uL of the deletion cassette (0.2-1 ug DNA) was 
immediately added to the competent cells and mixed with 100 uL of EZ3 solution. Cells 
were then incubated at 30°C for 1 hour with occasional vortexing and recovered in 500 uL 
YPD for 2 hours at 30°C in a rotator. Finally, cells were resuspended in 100 uL autoclaved 
water, spread onto the appropriate selection plates, and incubated at 30°C for 2-3 days. 
Strains used in this study were obtained through chemical transformation, sporulation, 
and/or mating (Table 2.1). 
 
Yeast drop test 
The wildtype diploid qCTF strain (RLY8494) and newly generated strains, JZ1270, and 
JZ1271, were streaked onto YPD plates and incubated at 30 C for 2 days. Single colonies 
were then inoculated in YPD and grown to saturation at 30 C overnight. Cultures were 
back-diluted, incubated for 5 hours on a rotator at 30°C and normalized to an OD600 of 
0.6. Serial 10-fold dilutions were made from the normalized cultures, and 7 uL of all 
dilutions were spotted onto drug-treated YPD plates (1% DMSO, 10 ug/mL radicicol, 0.05 
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ug/ml cycloheximide, 0.4 ug/mL 4-NQO, 10 ug/mL fluconazole, or 5 ug/mL benomyl). 
The treated plates were incubated at 30 C for two days and scanned. 
 
STRAIN GENOTYPE 
RLY8482 matα, MFA1_3xGFP::HIS5, minichromosome_LEU2 
RLY8494 MATa/matα, MFA1_3xGFP::HIS5, minichromosome_LEU2 
JZ1270 MATa/matαΔ::NatMX, pdr1Δ::TRP/pdr1Δ::TRP, pdr3Δ::URA3/ 
pdr3Δ::URA3,  erg6Δ::TRP1/erg6Δ::TRP1, minichromosome_LEU2 
JZ1271 MATa/matαΔ::NatMX, MAD2/mad2Δ::KanMX6, pdr1Δ::TRP/pdr1Δ::TRP, 
pdr3Δ::URA3/pdr3Δ::URA3,  erg6Δ::TRP1/erg6Δ::TRP1, 
minichromosome_LEU2 
JZ1324 RLY8494 STE11 del with KanMX6 
JZ1325 RLY8492 BMH1 del with KanMX6 
JZ1326 RLY8494 HOG1 del with KanMX6 
JZ1327 RLY8494 PBS2 del with KanMX6 
JZ1330 RLY8494 BMH1 del with KanMX6 
 
JZ1332 RLY8492 YLR345W del with KanMX6 
Table 2.1: Strains used in this study. For more details on strains RLY8492 and RLY8494 refer to 
Zhu, et al., 2015. 
 
 
High throughput kinase inhibitor screen procedure 
Kinase inhibitors were resuspended in DMSO to a final concentration of 1 mM and were 
aliquoted into five 96-well PCR plates such that the last column of all 96-well PCR plates 
contained only DMSO controls in order to control for edge effects. JZ1271 was inoculated 
into SD –leucine media to select for cells containing the minichromosome and allowed to 
grow at 30° C for 24 hours on a rotator. The initial GFP-positive frequency of the overnight 
culture was measured the next day using an Attune Nxt Flow Cytometer (Invitrogen). 
Overnight cultures were then back-diluted to an OD600 of 0.01 in SD media and 
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transferred into 96-deep well plates using a multichannel pipette. An EpMotion 5075 
automated liquid handler (Eppendorf) was then used to treated individual wells with kinase 
inhibitors for a final inhibitor concentration of 10 uM, 1% DMSO, or left untreated. The 
cultures were allowed to grow for 24 hours shaking at 200 rpm and 30°C. The final OD600 
was measured with a plate reader. Samples were then pelleted in a 96-well microtiter plate, 
fixed in an equal volume of 4% PFA for 15 minutes, washed twice with PBS supplemented 
with 1% YEP, and resuspended in an equal volume of PBS. During the fixation, samples 
were pelleted by centrifugation at 3000 rpm for 3 minutes and resuspended by shaking at 
1000 rpm for 3 minutes. Aliquots of fixed samples were diluted in PBS and samples from 
all four plates were compiled into a single 384 deep well plate using the automated liquid 
handler. The final GFP-frequency was then measured using an Attune Nxt Autosampler 
(Invitrogen), and the minichromosome loss rate was calculated for all samples. Four 
biological replicates were tested for each kinase inhibitor.  
 
Flow cytometry data collection  
0.3 million events were recorded for each sample in 1.5 mL Eppendorf tubes or 96-well 
microtiter plates. Cells were gated on FSC-H vs. SSC-H channels, single cells were gated 
on SSC-H vs SSC-A channels, and GFP-positive populations were gated on BLH1-H vs 
YLH1-H channels. 
 
Calculating minichromosome loss rate 
The initial GFP-positive frequency, final GFP-positive frequency, and number of 
generations (calculated from the initial OD and final OD) were used to calculate loss rate.  
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Loss rate m and generations n are given as: 
$ = 1 −	 )*+,)*+-
.




(refer to the “Measuring chromosomal instability in yeast” section in Chapter 1 for more 
details). 
 
High throughput screen data analysis  
To determine and remove outliers for each kinase inhibitor, leave-one-out cross validation 
(LOOCV) was used to evaluate the ratio of the final GFP-positive frequency (!#) to the 
initial GFP-positive frequency (!")  across all four biological replicates for each inhibitor. 
Briefly,	+-+, was calculated for all four biological replicates and a t-statistic was calculated 
for three randomly chosen biological replicates. The remaining replicate was excluded as 
an outlier if its  +-+,  ratio was not within the 95% confidence interval. The same method 
was used to exclude outliers in the number of generations for biological replicates. 
Replicates with negative generations were excluded since these cells either exhibit reduced 
growth or were killed under drug treatment. CIN rate was calculated for the remaining 
replicates and normalized to DMSO controls across all plates to determine the CIN fold 
change. The average CIN fold change of each inhibitor was calculated and inhibitors were 
ranked from lowest to highest CIN fold change. 
 
Cell sorting and auxotrophic growth assay 
JZ1271 (the qCTF strain used for the kinase inhibitor screen) was inoculated into SD -
leucine media and cultured on a rotator at 30°C for 24 hours. JZ1271 was then back-diluted 
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1:500 and treated with 1% DMSO (solvent control) or S1070 to a final concentration of 10 
uM and grown for 24 hours at 30°C. Gates were drawn for each sample based on their GFP 
profiles, and 300 cells from each gated population were sorted using a DakoCytomation 
MoFlo (Johns Hopkins University Flow Cytometry and Cell Sorting Core Facility) into 
liquid YPD media and plated onto individual YPD plates. After incubation in 30°C for 2 
days, the number of colony forming units per plate was counted using Fiji. Each YPD plate 
was then replica plated onto SD –leucine plates and grown in 30°C for 2 days. The number 
of colonies that grew on SD –leucine plates were counted to determine the percentage of 
colonies that retained the minichromosome.  
 
PI staining 
Staining with propidium iodide was performed by the JHU Flow Cytometry and Cell 
Sorting Core Facility immediately after cell sorting using standard protocols. 
 
Colony sectoring assay  
RLY4030 was streaked onto SD –uracil plates and incubated at 30 C for 2-3 days. A single 
colony was then inoculated into SD –uracil media and grown in 30 C overnight on a rotator. 
Cells were then refreshed in SD media the next day and allowed to double for 5 hours. 
Cells were back-diluted in 5 mL of SD media treated with the appropriate concentration of 
drugs for 5 hours (1 % DMSO, 10 ug/mL radicicol, 100 uM RAF265, 100 uM dabrafenib, 
100 uM MK-5108, or 100 uM PFK15). Cultures were then washed twice with water, 
resuspended in 1.5 mL autoclaved water and sonicated. The optical densities of the 
resuspended cultures were then measured, cultures were diluted to 2,400 cells per mL in 
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water, and plated onto 150 mm-diameter SC low adenine plates at 600 cells per plate. Plates 
were incubated at room temperature for 3 days, and stored at 4 C to allow sufficient time 
for pigment accumulation. Plates were then scanned and the total number of colonies per 
plate was quantified by Fiji. Colonies on the edges of the plate were excluded. Since cells 
deficient in adenine biosynthesis were observed to grow marginally slower, half-sectors 
were defined as colonies in which the red sector comprised more than 33% of the colony 
area (as quantified by Fiji). Chi-square analyses were performed in GraphPad to quantify 





Chapter 3: Results and Discussion 
Adapting the qCTF assay for a high throughput screen 
In order to identify inhibitors that increase chromosomal instability from a commercially-
available library of kinase inhibitors, the existing qCTF assay was modified to increase 
high throughput screening efficiency. The qCTF assay was previously used to test a small 
selection of compounds that were either known or speculated to elevate CIN (Zhu, et al., 
2015). Drug concentrations required to produce detectable fold changes in CIN were in the 
high micromolar range, occasionally requiring concentrations as high as 25 mM in order 
to detect 6-fold changes. The need for high drug concentrations highlights a major 
limitation of the qCTF assay for cost-effective high throughput compound screening. 
Notably, this limitation is not unique to the qCTF assay alone – various compound screens 
in yeast have encountered similar complications. In a small selective screen of 31 
anticancer drugs conducted in wildtype yeast, the IC50 was observed to be greater than 
100 uM for the majority of drugs and greater than 1 mM for approximately one quarter of 
the compounds tested (Simon, et al., 2000). Extensive studies have investigated various 
membrane transport proteins expressed on the plasma membrane of wildtype yeast that aid 
in pumping small molecules, including drugs and hormones, out of the cell (Ernst, Klemm, 
Schmitt, & Kuchler, 2005; Moye-Rowley, 2003; Nourani, Wesolowski-Louvel, Delaveau, 
Jacq, & Delahodde, 1997; Balzi & Goffeau, 1995). Efficient and cost-effective compound 
screens in yeast exploit the increased drug sensitivity conferred by the deletion of genes 
regulating drug efflux pumps and membrane permeability (Balzi & Goffeau, 1995; Perkins, 
et al., 2001; Dunstan, et al., 2002).  
To increase the drug sensitivity of the qCTF strain, three well-characterized  
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genes—ERG6, PDR1, and PDR3—were deleted and replaced with auxotrophic selection 
markers, TRYP1 (used redundantly) and URA3 (refer to Table 2.1). ERG6 is a 
methyltransferase involved in the biosynthesis of ergosterol, a component of the plasma 
membrane that contributes to its fluidity and permeability (McCammon, Hartmann, 
Bottema, & Parks, 1984; Emter, Heese-Peck, & Kralli, 2002; Sharma, 2006). The deletion 
of ERG6 has been shown to increase the passive diffusion of drugs across the plasma 
membrane (Emter, Heese-Peck, & Kralli, 2002). In contrast, pdr1 and pdr3 
transcriptionally regulate the expression of multi-drug resistance efflux pumps on the 
plasma membrane, thereby regulating the concentration of small molecules in the cell 
(Balzi & Goffeau, 1995). Deleting these three genes simultaneously increases membrane 
permeability while decreasing small molecule efflux, allowing for a higher local 
concentration of drugs inside the cell at low dosages of drug treatment. Moreover, the 
combinatorial deletion of these three genes is common in compound screens—as an 
example, the National Cancer Institute used a yeast strain containing these same gene 
deletions to identify small molecules that could selectively kill mutants deficient in double-
strand break repair mechanisms (Dunstan, et al., 2002).  
For the purpose of our study, we generated a diploid qCTF strain with homozygous 
deletions in ERG6, PDR1, and PDR3 (JZ1270). To test for drug sensitivity, a drop test was 
performed whereby serial dilutions of each strain were spotted onto YPD plates treated 
with individual drugs and the strains were allowed to grow for 2-3 days (Figure 3.1). The 
homozygous deletion mutant showed reduced growth on plates treated with 
cycloheximide, radicicol, 4-nitroquinoline 1-oxide, benomyl and DMSO (solvent control), 
indicating increased drug sensitivity to most drug treatments relative to the wildtype qCTF 
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Figure 3.1: Homozygous deletion of genes regulating membrane permeability and efflux pumps 
increases drug sensitivity. Drop tests were performed for two biological replicates of three different strains 
grown on YPD plates treated with 1% DMSO (solvent control), 10 ug/mL radicicol, 0.05 ug/ml 
cycloheximide, 0.4 ug/mL 4-NQO, 10 ug/mL fluconazole, or 5 ug/mL benomyl. The top two rows of each 
plate represent the wildtype qCTF strain with intact membrane and drug pumps, followed by two biological 
replicates of the qCTF strain with homozygous drug pump deletions, and two biological replicates of a drug 
sensitive qCTF strain containing a heterozygous deletion of MAD2. Columns represent serial 10-fold 
dilutions of each strain. 
 
 
strain. Interestingly, these homozygous drug pump deletions increase resistance to 
treatment with an FDA-approved antifungal agent, fluconazole (Vandeputte P. F., 2011). 
This is may be explained by reported observations that ERG6 mutants demonstrate 
increased resistance to fluconazole (Mukhopadhyay K. K., 2002). 
In addition to exhibiting increased drug resistance, yeast also have a robust 
surveillance mechanism to ensure the even distribution of genetic material during mitosis 
called the SAC (reviewed in Chapter 1). Failure to correct errors that arise during 
chromosome segregation often results in cell death. Thus, in order to observe increases in 




Figure 3.2: Heterozygous deletion of MAD2 weakens the mitotic checkpoint and increases basal CIN 
rate in yeast (p = 0.0014). Increasing drug sensitivity also imparts a 2.5-fold increase in the CIN rate (p 
<0.0001). All mutations are synergistic and increase CIN by roughly 6-fold (p = 0.0002).  n = 8 biological 
replicates per strain, treated with 1% DMSO. (* p < 0.01, ** p <0.001, *** p < 0.0001). Observed median 
CIN rates were 2.67E-5 per cell division for the wildtype qCTF strain, 6.57E-5 per cell division for the drug 




the robust mitotic checkpoint, thereby allowing the cell to tolerate errors that arise during 
cell division. Surprisingly, interfering with the expression of drug pumps and membrane 
permeability alone elevate CIN by roughly 2.5-fold (Figure 3.2). 
To further increase CIN, we deleted a crucial component of the spindle assembly 
checkpoint, MAD2 (reviewed in Chapter 1). A strain (JZ1271) with a heterozygous 
deletion of MAD2 and homozygous deletions of ERG6, PDR1, and PDR3 was generated 
and its basal CIN was determined. As predicted, the heterozygous MAD2 deletion allows 
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the cell to tolerate chromosomal missegregation events and demonstrates a synergistic 
effect with the homozygous drug pump deletions, providing an additional 2.5-fold increase 
in CIN (Figure 3.2). Consequently, the resulting strain elevated CIN by a total of 6-fold, 
with a median CIN rate of 1.73E-4 per cell division, and was chosen for our kinase inhibitor 
screen. 
 
Identifying hits from a primary screen 
The adapted qCTF assay was used to identify aneugens from a commercially-available 
library of 418 kinase inhibitors purchased from Selleckchem (refer to Chapter 2 for screen 
design). From our initial screen, we observed 20 kinase inhibitors that increase CIN by 
more than 5-fold, 16 inhibitors that increase CIN by more than 10-fold, and 2 inhibitors 
that increase CIN by more than 100-fold (Figure 3.3). Additionally, 3 inhibitors decreased 
CIN by 5-fold, resulting in CIN rates lower than 1.5	×10;<. However, because these low 
CIN measurements approached the detection limit of the modified qCTF assay, we could 
not demonstrate with statistical significance that these inhibitors decreased CIN. As a 
result, we focus only on kinase inhibitors that elevate CIN for the remainder of this study.  
Interestingly, tyrosine kinase inhibitors were amongst the top 10 kinase inhibitors 
that elevate CIN, two of which comprised the top two hits and target the mammalian kinase, 
c-met, for which there is no yeast homolog (Figure 3.4). In addition to tyrosine kinases 
(which make up approximately 25% of the kinase inhibitor library) other pathways that 
comprised the majority of our top hits include MAPK (11%) and mTOR (23%). Moreover, 
the kinase inhibitor hits that increase CIN by more than 5-fold are distributed across a wide 
array of pathways (Figure 3.4). 
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Figure 3.3: 20 kinase inhibitors increase CIN rate by more than 5-fold and up to about 200 fold. 
 
Figure 3.4: The distribution of pathways targeted by the top 20 kinase inhibitors reveal a diverse set 
of pathways that induce significant CIN fold changes, the common pathways being protein tyrosine 
kinase, MAPK and mTOR.  
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Although 20 kinase inhibitors increased CIN by more than 5-fold, abnormal GFP profiles 
were observed in several of these samples. Unidentified populations that span the gap 
between MC+ and MC- populations were observed and confounded the quantification of 
GFP-positive frequencies required for CIN calculations (Figure 3.5). Of the top 10 kinase 
inhibitors that increase CIN, 5 inhibitors gave rise to abnormal GFP profiles including our 
top two putative hits. Interestingly, all 5 inhibitors were yellow in color and 4 of the 5 
inhibitors were identified as tyrosine kinase inhibitors (Table 3.1). However, this was not 
a common GFP signature of all tyrosine kinase inhibitors since the tyrosine kinase inhibitor 
providing the next highest CIN fold increase (S1179) did not produce an abnormal GFP 
profile (Figure 3.5).  
 
 
Figure 3.5: Abnormal GFP profiles were observed in some treated samples. GFP profiles showing 
distinct GFP-positive (gated in black) and GFP-negative populations in samples treated with 1% DMSO 
(solvent control) or protein tyrosine kinase inhibitors (S1070, S1080, and S1179) that were yellow in color. 
Unexpected populations were observed in samples treated with tyrosine kinase inhibitors that comprised our 
top two putative hits, S1070 and S1080. In contrast, these abnormal profiles were absent in both the DMSO 
control and sample treated with S1179 – the next highest tyrosine kinase inhibitor producing the 28th highest 
increase in CIN. 
 
To investigate the source of these unidentified populations, we sorted cells from  
each population and tested the cells for the presence of an auxotrophic marker, LEU2, 




Table 3.1: Top 10 putative kinase inhibitors hits that elevate CIN, their pathways, targets and drug 
color. Half of the putative top hits are yellow in color, and 4 of the colored inhibitors target the tyrosine 
kinase pathway.   
 
screen (JZ1271) was treated with either solvent control (1% DMSO) or our putative top hit 
(S1070). Cells were then sorted into populations containing 300 cells per population: MC+, 
MC-, and any unidentified populations. Each population was grown on individual YPD 
plates and the resulting colonies were then counted and replica plated onto SD –leucine 
plates to quantify the percentage of cells that retained the mini chromosome. Only 6 of the 
300 cells from the unidentified populations grew into colonies, suggesting that the 
population consisted primarily of dead cells and indicating an initial overestimation of the 
GFP-positive population (Figure 3.6). A small decrease was observed in the MC- 
populations of both DMSO and S1070 treated samples, possibly as a result of cytotoxicity 
caused by high GFP expression. Moreover, a small percentage of the MC- population in 
all treated samples contained cells that have retained the minichromosome (about 5% on 
average). These relative proportions of these MC-positive cells is small and has minimal 
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Figure 3.6: Unidentified populations are comprised of dead cells. A) The GFP profiles of samples treated 
with 1% DMSO or 10 uM S1070 (the putative top hit) are depicted. Cells from GFP-negative, GFP-positive, 
and/or mystery populations were sorted (boxes indicate the populations that were collected) and plated onto 
YPD. B) Quantification of the colony forming units that arose from the 300 cells sorted show that the 
unidentified population is comprised of only 6 cells. Black bars indicate the total number of colony forming 
units, and white bars indicate the number of colonies that grew on SD – leucine plates. 
 
effects on the calculated CIN rate. To further reduce this percentage, we can increase the 
stringency of our gating to further increase the accuracy of our GFP-positive frequency 
measurements.  
The presence of dead populations was further validated by staining treated samples 
with an excitable viability dye, propidium iodide, which penetrates the damaged 
membranes of dead cells and intercalates into double stranded DNA (R&D Systems, 2017). 
Flow cytometry was used to detect cells that accumulated the viability dye and the 
percentage of dead cells was quantified (Figure 3.7). PI staining identified small  
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Figure 3.7: PI staining reveals that the unidentified population is comprised of dead cells stained with 
drug. The top row depicts the control sample treated with 1% DMSO and the bottom row depicts the sample 
treated with kinase inhibitor, S1070. The GFP profiles of each sample are shown before (left column) and 
after (right column) PI staining. 
 
percentages of dead cells in both the DMSO control and sample treated with 10 uM S1070. 
Notably, the absence of the unidentified population after PI staining suggests that the 
unidentified population is comprised of dead cells stained with the inhibitor. Taken 
together, cell sorting and viability staining suggest that the abnormal GFP profiles observed 
arose from dead cell populations that were stained by the colored kinase inhibitors and 
detected by the PE channel used. Staining of dead populations resulted in the 
overestimation of the population’s GFP-positive frequency and CIN. Subsequently, all 
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kinase inhibitors with abnormal GFP-positive profiles (S1070, S1080, S1421, S2845 and 
S1470) were excluded from the top hits (Table 3.1). Additional experiments conducted 
after the completion of the kinase inhibitor screen revealed that these dead populations of 
stained cells could be observed under the BLH2 channel. These results demonstrate the 
disadvantages of using fluorescence-based assays for compound screens and speak to the 
importance of obtaining measurements using multiple channels during the screening 
process to facilitate the identification of false positive hits afterwards. Moreover, screen 
design that allows for non-colorimetric validation of putative hits (i.e., phenotypic 
validation) provides additional routes of effective false positive hit identification.  
An additional parameter used to rule out false positives was the number of 
doublings undergone in 24 hours. Since opportunities for chromosomal missegregation 
only arise during mitosis and occur at a rate of approximately	1×10;=, a sufficient number 
of cell divisions is required for accurate CIN measurements.  More frequent cell divisions 
facilitate the accurate measurement of GFP-positive frequencies. Consequently, 24 of the 
remaining kinase inhibitors, which were observed to slow cell proliferation to fewer than 
4 generations in 24 hours, were removed from further analysis (Figure 3.8). Although these 
inhibitors were excluded from our screen for compounds that increase chromosomal 
instability, they may be useful as novel fungicides. Further testing in mammalian cells is 
required to investigate inhibitor cytotoxicity, selectivity, and potential for drug 
repurposing.  
After removing the false positive hits and drugs that inhibit cell growth and 
proliferation, we identified four kinase inhibitors hits that increase CIN by more than 5- 
fold (Figure 3.9). Our top two hits are both ATP-competitive inhibitors affecting the   
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Figure 3.8: 24 kinase inhibitors reduce cell proliferation to fewer than 4 generations in 24 hours. These 
inhibitors that slow cell growth and proliferation and were excluded from further analysis. 
 
MAPK pathway, which regulates cell proliferation, differentiation and apoptosis (Jin, 
Jiang, Rosen, Nelkin, & Ball, 2011; Holderfield, Nagel, & Stuart, 2014; Zhang & Liu, 
2002; Morrison, 2012). RAF265 produced the highest CIN fold change and has been shown   
to interfere with cell proliferation and tumor angiogenesis by inhibiting c-raf, wildtype b-
raf, and mutant b-raf (V600E) and preventing VEGFR2 phosphorylation with an IC50 in 
the nanomolar range (Table 3.2) (Williams, et al., 2015; Selleckchem, 2017). In the past 
decade, RAF265 has been tested in Phase II clinical trial by Novartis for the treatment of 
metastatic melanoma initiated in 2006 and in combination with other chemotherapy agents 
in 2011 (Pharmaceuticals, Novartis, 2016; Array BioPharma, 2016). Acting in the same 
pathway is dabrafenib, our second hit and selective FDA-approved inhibitor (IC50 = 0.65 
nM) for the treatment of melanomas harboring the BRAF V600E mutation 
(GlaxoSmithKline, 2014). In a phase III clinical trial, dabrafenib significantly increased  
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Figure 3.9: The remaining kinase inhibitor hits that increase CIN by more than 5-fold after 











progression-free survival to a median of 5 months in a cohort of 187 patients as compared  
with dacarbazine, which was the standard chemotherapy treatment for metastatic 
melanoma (Hauschild, et al., 2012). 
Our third hit is an Aurora A-specific kinase (IC50 = 0.064 nM) and ATP-
competitive inhibitor that interferes with a key regulator of mitosis and arrests the cell in 
G2/M phase (Shimomura, et al., 2010). Perturbations in the expression and function of 
aurora A have been demonstrated to cause chromosomal instability. Overexpression of 
Aurora A is observed in numerous human cancers, including breast, ovarian, colorectal and 
skin, and has been implicated in conferring drug resistance to Taxol, a commonly 
administered chemotherapy agent (Nikonova, Astsaturov, Serebriiskii, Dunbrack, & 
Golemis, 2013; Anand, Penrhyn-Lowe, & Venkitaraman, 2003). Additionally, silencing 
Aurora A causes centrosome missegregation, abnormal spindle assembly, and 
chromosomal misalignment (Marumoto, et al., 2003). Given that reduction in Aurora A 
expression has been implicated in chromosomal instability, this inhibitor is a positive hit 
that provides further validation in support of the hits identified by our screen. Notably, this 
Aurora A kinase inhibitor demonstrates anti-tumorigenic activity, showing promising 
results in a recently completed phase I study for use as monotherapy and combination 
therapy with docetaxel to treat advanced solid tumors (Shimomura, et al., 2010; Amin, et 
al., 2016).  
Our final hit is a 6-phosphofructo-2 kinase (PFKFB3) inhibitor, which has a high 
IC50 of 207 nM (Clem, et al., 2013). PFKFB3 is overexpressed in aggressive breast, 
ovarian, and thyroid cancers and has been shown to promote cell cycle progression (Yalcin, 
et al., 2014; Atsumi, et al., 2002). Studies have demonstrated that inhibition of PFKFB3 in 
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HeLa cells reduces glycolysis and glucose uptake, decreases cell proliferation, and induces 
apoptosis (Yalcin, et al., 2014).  Moreover, PFKFB3’s role in increasing cell proliferation 
is not limited to its production of 2,6-biphosphate, an activator of glycolysis, and has been 
implicated in modulating p27 expression in the nucleus through proteasome degradation 
(Yalcin, et al., 2014). Consequently, many studies have explored the suppression of 
PFKFB3 as a potential cancer therapeutic leading to a phase I clinical trail initiated in 2014 
for the use of a newly optimized PFKFB3 inhibitor, PFK-158, to treat advanced solid 
malignancies  (Clem, et al., 2013; Redman, Pohlmann, Kurman, Tapolsky, & Chesney, 
2015). Although PFKFB3 has been linked to cancer through increased glucose metabolism 
and suppression of apoptosis, how it induces chromosomal instability remains unknown. 
 
Validation of top hits using a classical qCTF assay 
Each of the hits was verified using a classical chromosome transmission fidelity assay 
(described in Chapter 1). A haploid CTF strain harboring an ade2-101 mutation and a 
chromosome fragment containing SUP11 (as previously used by Spencer et. al., 1999 and 
Zhu et. al., 2015) was used to validate our top hits. This strain was treated with either 
solvent control (1% DMSO) or inhibitors, and the percentage of half sectors was measured 
in order to determine CIN rate (Figure 3.10). The the rate of CF loss during the first cell 
division after plating (as indicated by half-sectors) was used as a proxy for average CIN 
rate. 
As a positive control, we show that treatment with 10 ug/mL radicicol increases the 
percentage of half-sectors by a factor of 10-fold more than the DMSO solvent control (p-




















12 3417 0.0001 
100 uM RAF265 0.00131406 7610 10 7600 0.0051 
100 uM 
Dabrafenib 
0.001170235 29054 34 29020 0.0002 
100 uM MK-5108 0.000937165 44816 42 44774 0.0049 
100 uM PFK15 0.001507917 3979 6 3973 0.0087 
 
Figure 3.10: Colony sectoring assay verifies top four kinase inhibitor hits. p-values indicated are obtained 
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increases the percentage of half sectors by 6-fold (p-value = 0.0064). As expected, the CIN  
fold change induced by our top hit as measured by the colony color CTF is about 10-fold 
less than the CIN fold change measured by the modified qCTF. The large difference is 
likely due to the decreased drug sensitivity of the classical CTF strain relative to the strain 
used for our drug screen. The classical CTF assay validated all of our top 4 hits, suggesting 
that our combination of qCTF assay modification, statistical analysis and false-positive 
exclusion methods can effectively detect and identify compounds that significantly 
increase chromosomal instability in yeast. 
 
Elucidating novel pathways that contribute to CIN in budding yeast 
The library used in this high throughput screen was comprised of mammalian kinase 
inhibitors whose targets have not been identified in budding yeast. To elucidate pathways 
contributing to chromosomal missegregation in yeast, yeast genes with some homology or 
structural similarity to each inhibitor’s known mammalian targets were deleted in wildtype 
diploid (RLY8494) and haploid (RLY8492) qCTF strains containing the mini chromosome. 
The CIN rate of these deletion strains was investigated by qCTF assay in order to identify 
possible yeast targets of our top mammalian hits.  
Two of our four hits target raf and perturb the MAPK pathway (Table 3.3), which 
mediates cellular response to environmental cues by coupling inputs from cell surface 
receptors to transcriptional regulators in the nucleus (Molina & Adjei, 2006). Components 
of the MAPK pathway in yeast – STE11, BMH1, PBS2, and HOG1 – were initially chosen 
for further investigation as drug targets and as potential mediators of chromosomal 
instability. STE11 is a MEKK that shares structural similarity with mammalian MAPKKKs  
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Table 3.3: Potential drug targets in yeast. 
 
and acts in 3 of the 5 MAPK pathways – pheromone response, filament invasion, and high- 
osmolarity growth pathways (Herskowitz, 1995; Gustin, Albertyn, Alexander, & 
Davenport, 1998). It was chosen as a likely target of our raf inhibitors because of its 
extensive involvement in the MAPK pathway and homology with mammalian MAPKKKs. 
BMH1 is one of two yeast isoforms of 14-3-3 proteins, a family of highly conserved 
proteins involved in various cellular functions including vesicle trafficking, protein 
localization, cytokinesis, and stress response (van Heusden & Yde Steensma, Yeast 14 3
3 proteins, 2006). The first 250 residues of Bmh1p in particular share 91% identity with 
the mammalian 14-3-3ε isoform, which is crucial for mitotic timing in drosophila (van 
Heusden & Yde Steensma, Yeast 14 3 3 proteins, 2006; Hermeking, 2003). The yeast 
MEK and MAPK homologs, PBS2 and HOG1, respectively, are components of the 
MAPK’s HOG pathway (Herskowitz, 1995). PBS2 is a scaffold protein that binds both 
STE11 and HOG1, and aids in signal transduction from osmolarity-sensitive receptors to 
HOG1 (Lodish, 2000). Furthermore, PBS2 activates HOG1, which regulates the expression 
of stress response genes induced by increased osmolarity (Gustin, Albertyn, Alexander, & 
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Davenport, 1998). Because the MAPK pathway is extensive, these four genes were chosen 
as an initial starting point and we expect to expand our current list to components in other 
MAPK pathways.  We previously observed that the deletion of genes regulating drug efflux 
pumps produces a 2-fold elevation in CIN. As a result, we are interested in investigating 
components in the MAPK’s cell wall integrity pathway in the future.  
Our third hit inhibits an aurora kinase, for which only one exists in yeast. 
Discovered in a screen for mutants with abnormal chromosome segregation, IPL1 
(increase-in-ploidy 1) aids in correcting improper chromosome-spindle associations by 
destabilizing the attachments between microtubules and kinetochores through 
phoshporylation (Chan & Botstein, 1993; Musacchio & Salmon, 2007). Studies suggest 
that destabilization may be driven by the lack of tension at the kinetochore during sister 
chromatid separation (Musacchio & Salmon, 2007). Destabilization of microtubule-
kinetochore attachments by IPL1 generates unattached kinetochores, activating the spindle 
assembly checkpoint and allowing the cell sufficient time to correct mitotic errors 
(Musacchio & Salmon, 2007). 
 Our final hit targets the AMPK signaling pathway and inhibits a phosphofructo-
kinase, PFKFB3, that produces an activator of glycolysis. YLR345W is a 6-
phosphofructose-2-kinase enzyme that is predicted to synthesize fructose 2,6-bisphosphate 
(UniProt Consortium, 2017). Although YLR345W is an uncharacterized ORF, the p arm 
of YLR345W is similar in sequence to that of the mammalian 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphate enzymes – the  closest relative being PFKFB4 in rats 
(BLAST E-value = 5×10;= ) (Zaim, Speina, & Kierzek, 2005). Interestingly, studies have 
shown that YLR345W links stress-induced glucose metabolism and DNA damage 
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response through a DNA-binding protein, CRT1 (Zaim, Speina, & Kierzek, 2005). 
However, whether YLR345W plays a role in inducing chromosome missegregation is 
unknown. 
In order to further elucidate the pathways by which these inhibitors elevate CIN in 
yeast, homozygous and heterozygous deletion mutants were generated for each of the yeast 
non-essential genes, STE11, BMH1, PBS2, HOG1, and YLR345W. Of the heterozygous 
deletions, HOG1 was found to significantly elevate CIN by a median of 1.60-fold (Figure 
3.11). This increase in CIN may be explained by HOG1’s role in mediating cell cycle arrest. 
HOG1 homozygous deletion mutants will be tested in order to elucidate how these cells 
respond to increases in extracellular osmolarity and its implications in maintaining 
chromosomal segregation fidelity (data pending). 
 
Figure 3.11: Heterozygous and homozygous deletions of MAPK components suggest that HOG1 and 
BMH1 may be potential mediators of chromosomal instability. Heterozygous HOG1 deletion produced 
a significant 1.6-fold increase in CIN (p<0.0001) and homozygous deletion of BMH1 produced a 1.27-fold 
elevation in CIN (p = 0.0071) (all samples were untreated). Boxplots are depicted with median fold change 
represented by the middle bars and individual dots representing fold change observed in each of the biological 
replicates. Other homozygous deletion mutants are pending. 
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To observe more exaggerated CIN phenotypes, we individually deleted each non- 
essential gene in a haploid qCTF strain (RLY8492). Homozygous deletion of BMH1 in a 
haploid background produced a 1.27-fold elevation in CIN even though no significant 
increase was observed in the BMH1 heterozygous deletion mutant, suggesting that one 
copy of BMH1 is sufficient to maintain chromosome transmission fidelity (Figure 3.11). 
To provide further evidence that BMH1 may be a drug target, the BMH1 homozygous 
deletion mutant will be treated with either RAF265 or dabrafenib and tested using the qCTF 
assay. Elevations in CIN should not be observed if BMH1 is a target. The increases in CIN 
observed in the homozygous BMH1 deletion mutant is supported by a recent study, which 
demonstrated that BMH1 is necessary for symmetric localization of spindle pole bodies in 
yeast (Caydasi, Micoogullari, Kurtulmus, Palani, & Pereira, 2014). Furthermore, the same 
study proposed BMH1 as an additional component of the SPOC (spindle position 
checkpoint) that ensures the proper alignment of the the mitotic spindle along the poles 
prior to cell division (Caydasi, Micoogullari, Kurtulmus, Palani, & Pereira, 2014).  
 The non-essential gene, YLR345W, was deleted in a diploid and haploid 
background to test its potential as a target of PFK15. Significant increases in CIN were not 
observed, suggesting that this gene does not play a critical role in chromosome partitioning 
(Figure 3.12). Other yeast 6-phoshpofructo-2-kinases enzymes, such as PFK26 and PFK27, 
will be tested in the future.  
To identify the yeast target of the Aurora A inhibitor, MK-5108, heterozygous IPL1 
deletion mutants were generated in a wildtype diploid qCTF background since IPL1 is an 
essential gene. Interestingly, increases in CIN were not observed upon heterozygous 




Figure 3.12: YLR345W is not required for proper chromosome segregation. Both YLR345W 
heterozygous and homozygous deletion mutants do not produce significant elevations in CIN. 
 
maintain chromosome transmission fidelity in yeast and further reductions in IPL1 
expression would increase CIN. The IPL1 heterozygous deletion mutant was then treated 
with different concentrations of MK-5108 to test if additional reduction of functional IPL1 
would significantly increase CIN. Treatment with 100 uM MK-5108 increased CIN in the 
IPL1 deletion mutant by a median of 1.50-fold (p= 0.0034) more than the wildtype under 
the same treatment conditions, suggesting that the mammalian aurora A inhibitor may be 
interacting with its homolog in yeast. Increases in CIN were not observed between the 
heterozygous deletion mutant and wildtype under other treatment conditions (10 uM MK-
5108, DMSO treatment, or untreated). Moreover, significant 1.37-fold increases were also 
observed between heterozygous IPL1 deletion mutants treated with 100 uM inhibitor and  
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Figure 3.13: CIN of heterozygous IPL1 deletion mutant treated with aurora A kinase inhibitor, MK-
5108. Mutants treated with 100 uM inhibitor show a significant 1.50-fold median elevation in CIN relative 
to wildtype strains treated with the same concentration of inhibitor (p = 0.0034). Treatment of the IPL1 
mutant with 100 uM inhibitor also produces a significant 1.61-fold median increase in CIN relative to 
treatment of the mutant with the DMSO control (p= 0.0023) (not shown). A significant difference was also 
observed when the IPL1 mutant was treated with 10 uM and 100 uM inhibitor (p = 0.0061) (not shown).  
 
 
10 uM inhibitor, indicating that high drug dosage is required to elicit detectable responses 
in wildtype yeast in order to account for robust drug efflux. Taken together, this data 
suggests that MK-5108 may target IPL1 in yeast, and corroborates literature demonstrating 
that reductions in functional IPL1 increases chromosomal instability (Chan & Botstein, 
1993). Additional biochemical assays demonstrating IPL1 binding to the inhibitor must be 




Chapter 4: Conclusions 
Summary 
In this study, we identify four kinase inhibitors that significantly increase chromosome 
missegregation and propose pathways that may be implicated in maintaining faithful 
chromosome partitioning. We demonstrate the versatility of the qCTF assay by adapting it 
for high throughput screening through increasing drug sensitivity and weakening the 
mitotic checkpoint. We then developed a pipeline for cost-effective screening, false 
positive exclusion, hit verification, and identification of aneugens in budding yeast. During 
the hit identification process, we encountered and addressed a weakness of many 
fluorescence-based assays. Additional phenotypic validation assays and cell sorting 
experiments showed that interference from colored drugs may generate false positives; 
however, these complications could be resolved by examining GFP profiles, using 
additional channels during flow cytometry, and/or staining with a viability dye. From our 
identified hits, we came up with possible drug targets based on inhibitors’ known 
mammalian targets to identify novel genetic modulators of CIN. Finally, we propose that 
components of the MAPK pathway, HOG1 and BMH1, may be involved in maintaining 
faithful chromosome segregation. 
 
Future directions 
In the future, we aim to improve the current qCTF assay by increasing its dynamic range 
and accuracy in measuring CIN. We propose to continue challenging the limits of the 
dynamic range by increasing the basal CIN rate of the adapted qCTF strain. The capacity 
to observe significant reductions in MC loss rate will allow us to identify genome 
protective compounds that decrease CIN and may prevent cancer development. 
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Furthermore, the mathematical model used in this study to calculate CIN assumed equal 
doubling times between MC+ and MC- populations. However, 27 kinase inhibitors in our 
screen produced negative CIN values, suggesting that fitness differences exist between the 
two populations. To account for this competition, we are developing a calibration strain 
with a different reporter (RFP) that matches the genotype and karyotype of MC- cells. By 
tracking the growth of the calibration strain, we can predict the growth of the MC- 
population and correct for differences in doubling times to obtain more accurate CIN 
measurements (refer to Zhu, et al., 2015 for the mathematical model and related equations). 
Additionally, to study how our kinase inhibitor hits affect chromosome partitioning 
in more complex systems, we aim to investigate these hits in mammalian cell lines by 
performing chromosome spreads and live-cell imaging experiments. Observing 
chromosome missegregation events in real time may provide hints as to how each hit 
interferes with the segregation machinery. Finally, we hope to extend the current high 
throughput pipeline to larger libraries of FDA-approved compounds and natural products 
to identify genome protective compounds, repurpose existing drugs, and/or caution against 
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